NasdaqGS - Nasdaq Real Time Price • USD
Arcellx, Inc. (ACLX)
As of 3:18 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 14 | 14 |
| Avg. Estimate | -0.51 | -0.53 | -1.94 | -2.01 |
| Low Estimate | -0.95 | -1 | -4.1 | -4.6 |
| High Estimate | -0.19 | -0.21 | 0.29 | 1.35 |
| Year Ago EPS | -0.58 | -0.5 | -1.47 | -1.94 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 12 | 12 |
| Avg. Estimate | 20.67M | 19.83M | 106.51M | 122.9M |
| Low Estimate | 15M | 15M | 59.8M | 60M |
| High Estimate | 34.7M | 34.7M | 203.41M | 279.75M |
| Year Ago Sales | 17.91M | 40.55M | 110.32M | 106.51M |
| Sales Growth (year/est) | 15.40% | -51.10% | -3.50% | 15.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.82 | -0.31 | -0.54 | -0.61 |
| EPS Actual | -0.58 | -0.5 | -0.81 | 0.42 |
| Difference | -2.4 | -0.19 | -0.27 | 1.03 |
| Surprise % | -131.90% | -61.30% | -50.00% | 168.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.51 | -0.53 | -1.94 | -2.01 |
| 7 Days Ago | -0.51 | -0.53 | -1.94 | -2.01 |
| 30 Days Ago | -0.54 | -0.55 | -1.98 | -2.01 |
| 60 Days Ago | -0.63 | -0.63 | -2.2 | -2.55 |
| 90 Days Ago | -0.63 | -0.63 | -2.2 | -2.55 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACLX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 12.10% | -- | -- | 1.50% |
| Next Qtr. | -6.00% | -- | -- | 12.10% |
| Current Year | -32.00% | -- | -- | 4.40% |
| Next Year | -3.60% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 69.30% | -- | -- | 10.97% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
| Maintains | Needham: Buy to Buy | 3/18/2024 |
| Reiterates | Stifel: Buy to Buy | 3/14/2024 |
| Initiated | Morgan Stanley: Overweight | 3/7/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/5/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/29/2024 |
Related Tickers
NUVL Nuvalent, Inc.
66.64
+0.86%
KYTX Kyverna Therapeutics, Inc.
15.75
-1.19%
CGEM Cullinan Therapeutics, Inc.
25.13
+30.55%
MLTX MoonLake Immunotherapeutics
42.54
+0.69%
IMCR Immunocore Holdings plc
57.79
-0.36%
PCVX Vaxcyte, Inc.
60.39
+0.55%
CRGX CARGO Therapeutics, Inc.
18.67
+2.13%
CGON CG Oncology, Inc.
40.86
+12.87%
APGE Apogee Therapeutics, Inc.
46.84
+2.14%
SWTX SpringWorks Therapeutics, Inc.
45.55
+3.05%